Tech Company Financing Transactions

True North Therapeutics Funding Round

True North Therapeutics, based in South San Francisco, raised $22 million from Baxter Ventures, Biogen Idec and Kleiner Perkins Caufield & Byers.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

951 Gateway Blvd.
South San Francisco, CA 94080
USA

Phone

(650) 872-4700

Website

www.truenorthrx.com

Email Address

[email protected]

Overview

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company's lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Nancy Stagliano

        

Chief Financial Officer

Pamela Wapnick

        

Chief Medical Officer

Gary Patou

        

VP - Bus. Development

Adam Rosenthal

        

VP - R & D

Graham Parry

        

Browse more venture capital transactions:

Prev: 6/17/2014: HighRoads venture capital transaction
Next: 6/17/2014: PowerVision venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary